Drug Search Results
Using advanced filters...
Advanced Search [+]

VIR-1111

Alternative Names: vir-1111, vir1111, vir 1111
Clinical Status: Inactive
Latest Update: 2023-09-20
Latest Update Note: News Article

Product Description

VIR-1111 is being developed by Vir Biotechnology for the treatment of patients with HIV I Infection. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04725877?term=VIR-1111&draw=2&rank=1)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vir Biotechnology
Company Location: SAN FRANCISCO CA 94158
Company CEO: George Scangos
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Acquired Immunodeficiency Syndrome|HIV Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

VIR-1111

P1

Completed

Acquired Immunodeficiency Syndrome|HIV Infections

2022-12-05

36%

2023-02-28

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status